<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00373451</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. A01106</org_study_id>
    <nct_id>NCT00373451</nct_id>
  </id_info>
  <brief_title>Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome</brief_title>
  <acronym>ISAR-REACT-4</acronym>
  <official_title>Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which of these anti-clotting medications, abciximab
      plus unfractionated heparin or bivalirudin, is more effective to prevent thrombotic and
      bleeding complications in patients suffering from a heart attack and undergoing coronary
      intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-ST elevation myocardial infarction (NSTEMI) is associated with an increased risk of death
      and is a major reason for hospital admissions. Most frequently, the sequence of events that
      leads to NSTEMI is characterized by a disrupted atherosclerotic plaque, platelet activation
      and aggregation, thrombus formation and microembolizations. Patients with NSTEMI are treated
      with an early invasive strategy and there is intensive work in progress to define the optimal
      antithrombotic therapy to be used in adjunct to percutaneous coronary intervention (PCI) in
      these patients. Bivalirudin, a direct thrombin inhibitor, and the glycoprotein IIb/IIIa
      inhibitor (GPI) abciximab have been in the focus of recent trials in patients with acute
      coronary syndrome (ACS). In a recent randomized, open-label trial (ACUITY trial), patients
      with the suspicion of ACS on the basis of the type of anginal symptoms, ST-segment
      displacement, elevated biomarkers or several risk indicators were randomized to receive
      bivalirudin alone with bail-out GPIs, bivalirudin plus GPIs, or heparin/low-molecular weight
      heparin plus a GPI. The GPIs most frequently used were eptifibatide and tirofiban. Abciximab
      was given in only &lt; 9% of the cases. In another randomized, double-blind, placebo-controlled
      trial (ISAR-REACT-2) including ACS patients undergoing PCI, abciximab was administered in
      cath lab and was associated with a significant reduction of ischemic events in patients with
      NSTEMI, and did not lead to a measurable increase in major bleeding complications. However,
      it is not known whether abciximab is also superior to bivalirudin in patients with NSTEMI. We
      designed this study to assess whether abciximab added to unfractionated heparin is superior
      to bivalirudin in patients with NSTEMI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of death, large recurrent myocardial infarction (MI), urgent target vessel revascularization (TVR) or major bleeding</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite end point of death, any recurrent myocardial infarction or urgent TVR</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleedings</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1721</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Abciximab+UFH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abciximab and unfractionated heparin as bolus given during PCI and abciximab-perfusion for 12 hours after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bivalirudin given only during PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab + UFH</intervention_name>
    <description>Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute [maximum of 10 µg/minute] infusion for 12 hours)</description>
    <arm_group_label>Abciximab+UFH</arm_group_label>
    <other_name>ReoPro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)</description>
    <arm_group_label>Bivalirudin</arm_group_label>
    <other_name>Angiox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>i.v. bolus of 70 units/kg/body weight of unfractionated heparin</description>
    <arm_group_label>Abciximab+UFH</arm_group_label>
    <other_name>unfractionated heparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Episode of unstable angina

          -  Elevated cardiac markers

          -  Angiographic lesions requiring PCI

          -  Informed, written consent

        Exclusion Criteria:

          -  Age &lt; 18 years and &gt; 80 years

          -  ST-segment elevation acute myocardial infarction within 48 hours

          -  Cardiogenic shock

          -  Pericarditis

          -  Malignancies or other comorbid conditions with life expectancy less than one year or
             that may result in protocol non-compliance

          -  Active bleeding; bleeding diathesis; history of gastrointestinal or genitourinary
             bleeding, recent trauma or major surgery in the last month; history of intracranial
             bleeding or structural abnormalities; suspected aortic dissection; pericarditis; and
             patient's refusal to blood transfusion

          -  Oral anticoagulation therapy with coumarin derivative within the last 7 days

          -  Recent use of GPIIb/IIIa inhibitors within 14 days

          -  Treatment with unfractionated heparin within 4 hours unless ACT &gt; 150sec; or
             low-molecular weight heparin within 8 hours before randomization

          -  Treatment with bivalirudin within 24 hours before randomization

          -  Severe uncontrolled hypertension &gt; 180/110 mm Hg unresponsive to therapy

          -  Planned staged PCI procedure within 30 days from index procedure or prior PCI within
             the last 30 days

          -  Relevant hematologic deviations

          -  Glomerular filtration rate (GFR) &lt; 30 ml/min or serum creatinine &gt; 30 mg/L or
             dependence on renal dialysis

          -  Known allergy or intolerance to the study medications, stainless steel or true
             anaphylaxis after prior exposure to contrast media

          -  Previous enrollment in this trial

          -  Women who are known to be pregnant, who are of childbearing potential and test
             positive for pregnancy, who have given birth within the last 90 days, who are
             breastfeeding

          -  Patient's inability to fully cooperate with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schoemig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herz-Zentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefaessklinik, Kardiologie</name>
      <address>
        <city>Bad Neustadt</city>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Auguste Viktoria Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukoelln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Osnabrueck</name>
      <address>
        <city>Osnabrueck</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cageggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr; American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002 Oct 2;40(7):1366-74.</citation>
    <PMID>12383588</PMID>
  </reference>
  <reference>
    <citation>Schulman SP. Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. JAMA. 2004 Oct 20;292(15):1875-82.</citation>
    <PMID>15494586</PMID>
  </reference>
  <reference>
    <citation>Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP, Schmitt C, Seyfarth M, Dirschinger J, Schömig A. Evaluation of prolonged antithrombotic pretreatment (&quot;cooling-off&quot; strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA. 2003 Sep 24;290(12):1593-9.</citation>
    <PMID>14506118</PMID>
  </reference>
  <reference>
    <citation>Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005 Apr;26(8):804-47. Epub 2005 Mar 15.</citation>
    <PMID>15769784</PMID>
  </reference>
  <reference>
    <citation>Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006 Apr 5;295(13):1531-8. Epub 2006 Mar 13.</citation>
    <PMID>16533938</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2006</study_first_submitted>
  <study_first_submitted_qc>September 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2006</study_first_posted>
  <last_update_submitted>May 7, 2012</last_update_submitted>
  <last_update_submitted_qc>May 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSTEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

